Results 171 to 180 of about 13,748 (197)

Case Report: Metastasis to pleura and mediastinal lymph nodes from breast secretory carcinoma: 10 years follow-up. [PDF]

Front Oncol
Huang F, Zhao J, Lian J, Hong B, Yu X, Ma X, Lai J, Qian W, Tu J, Qiu F, Zou H, Huang J, Li J.   +12 more
europepmc   +1 more source

Novel NOTCH2-NTRK1 fusion confers osimertinib resistance in EGFR-mutant non-small cell lung cancer by interacting with EGFR. [PDF]

Transl Oncol
Li H, Wei H, Zhen T, Gao H, Liu H, Zheng S, Shi H, Liang J, Zhang F, Ye J, Lin G, Han A.   +11 more
europepmc   +1 more source

Bridging East and West: Real-World Clinicogenomic Landscape of Metastatic NSCLC in Türkiye. [PDF]

Genes (Basel)
Canaslan K, Eken E, Bilici M, Balcıoğlu FM, Öztürk B, Çakmak M, Bal Ö, Turhan G, Özdemir F, Arvas H, Urakçı Z, Çiçek E, Turna ZH, Karaoğlu A.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Infantile NTRK -associated Mesenchymal Tumors

Pediatric and Developmental Pathology, 2017
Pediatric fibroblastic/myofibroblastic lesions are a relatively common group of tumors with varying morphologies, for which the molecular mechanisms are becoming increasingly well characterized. Congenital infantile fibrosarcoma (CIFS), perhaps the most well studied of these lesions is characterized by a recurrent ETV6-NTRK3 gene fusion.
Jessica L, Davis, Christina M, Lockwood, Catherine M, Albert, Karen, Tsuchiya, Douglas S, Hawkins, Erin R, Rudzinski   +5 more
openaire   +2 more sources

NTRK point mutations and their functional consequences

Cancer Genetics, 2022
The neurotrophic receptor tyrosine kinase (NTRK) family of genes, including NTRK1, NTRK2, and NTRK3, encodes membrane-bound receptors that normally regulate cell survival and differentiation upon binding of growth factors. Not surprisingly, mutations in these genes are known to contribute to the growth of a diverse number of cancers.
Corey, Rogers, Jennifer J D, Morrissette, Robyn T, Sussman   +2 more
openaire   +2 more sources

[NTRK Gene Fusions and Treatment in NTRK Fusion-Positive Solid Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy, 2022
Neurotrophic tyrosine receptor kinase(NTRK)gene variants have been reported in a variety of cancer types. The prevalence of NTRK gene variants is less than 1% in many types of solid cancer. The highest NTRK gene fusions frequencies were found in secretary breast carcinoma and infantile fibrosarcoma.
Misao, Fukuda, Yoichi, Naito
openaire   +1 more source

173P Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer

2022
BackgroundFusions in the neurotrophic tyrosine receptor kinase (NTRK) genes act as oncogenic drivers in many solid tumours, including secretory and non-secretory breast cancers. In the phase 2 STARTRK-2 clinical trial (NCT02568267), entrectinib (a TRK inhibitor with CNS activity) induced objective responses in 83.3% of patients (pts) with NTRK-fp ...
Lu, J., Blakely, C.M., Barve, M., Chung, C.H., Waqar, S.N., Hu, X., Delord, J-P., Krzakowski, M.J., Yonemori, K., Chen, D.T., Klingbiel, D., Heinzmann, S., Le Tourneau, C.   +12 more
openaire   +1 more source

NTRK-Fusions – A new kid on the block

Pathology - Research and Practice, 2019
The neurotrophic tyrosine receptor kinases (NTRK) play an important role in the development and function of the nervous system. Fusions involving NTRK and a wide range of genes that act as fusion partners are oncogenic and activate well-known signal transduction pathways like the MAPK-ERK pathway.
Märkl, Bruno, Hirschbühl, Klaus, Dhillon, Christine   +2 more
openaire   +2 more sources